Module 5, Section 1: Property-Based Design

Key Takeaways

• Ligand Efficiency (LE) quantifies binding energy per heavy atom.
• Lipophilic Ligand Efficiency (LLE) balances potency against lipophilicity.
• MRTX‑1719 showcases LE optimization for PRMT5 inhibition.
• Lorlatinib demonstrates macrocyclic design improving LLE for ALK targets.

Pulse Analysis

Property‑based design has become a cornerstone of modern medicinal chemistry, shifting focus from sheer potency to a holistic view of a molecule’s physicochemical profile. By correlating ligand size, lipophilicity, and binding affinity, researchers can predict how a candidate will behave in vivo, reducing late‑stage attrition. Metrics such as Ligand Efficiency (LE) and Lipophilic Ligand Efficiency (LLE) translate these relationships into actionable numbers, enabling teams to compare disparate scaffolds on a common scale and prioritize compounds that deliver the most therapeutic value per atom.

LE measures the binding energy contributed by each non‑hydrogen atom, encouraging compact, high‑affinity structures. LLE extends this concept by subtracting the compound’s logP from its pIC50, rewarding potency that does not come at the expense of excessive lipophilicity—a key driver of poor solubility and metabolic instability. Together, these metrics guide medicinal chemists in trimming unnecessary bulk, optimizing hydrogen‑bond networks, and selecting functional groups that enhance selectivity without inflating the lipophilic burden. The result is a more predictable pharmacokinetic profile and a smoother path through regulatory scrutiny.

The lecture’s case studies illustrate theory in practice. MRTX‑1719, a PRMT5 inhibitor, achieved high LE by leveraging a minimalist scaffold that retained nanomolar potency while keeping molecular weight low, facilitating oral dosing. Conversely, lorlatinib’s macrocyclic architecture exemplifies how strategic ring closure can boost LLE, delivering potent ALK inhibition with moderated lipophilicity, which translates to favorable brain penetration and reduced off‑target effects. Both programs underscore that disciplined metric‑driven design not only shortens discovery timelines but also yields candidates with superior safety and commercial prospects, setting a benchmark for future drug development initiatives.